|
Press Releases |
|
 |
|
Friday, June 13, 2025 |
|
Jacobson Pharma Announces FY2025 Annual Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing, and sale of essential medicines and specialty drugs, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2025 ("FY2025" or the "Reporting Period"). more info >> |
|
雅各臣公佈二零二五財年全年業績 持續經營業務溢利飈升43.1%至3.0億港元 |
從事基礎藥物及專科藥物研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司(「雅各臣」或「公司」;股份代號:2633.HK)今天公佈公司及其附屬公司(統稱「集團」)截至二零二五年三月三十一日止年度(「二零二五財年」或「報告期」)的全年業績。 more info >> |
|
雅各臣公布二零二五财年全年业绩 持续经营业务溢利飙升43.1%至3.0亿港元 |
从事基础药物及专科药物研发、生产、市场推广及销售的领先企业 ─ 雅各臣科研制药有限公司(「雅各臣」或「公司」;股份代号:2633.HK)今天公布公司及其附属公司(统称「集团」)截至二零二五年三月三十一日止年度(「二零二五财年」或「报告期」)的全年业绩。 more info >> |
|
Friday, November 22, 2024 |
|
Jacobson Pharma Announces FY2025 Interim Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines and specialty drugs, today announced the interim results of the Company and its subsidiaries (collectively, the "Group") for the six months ended 30 September 2024 (the "Reporting Period"). more info >> |
|
雅各臣公佈二零二五財年中期業績 持續經營業務溢利飈升44.2% |
從事基礎藥物及專科藥物研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司(「雅各臣」或「公司」;股份代號:2633.HK)今天公佈公司及其附屬公司(統稱「集團」)於截至二零二四年九月三十日止六個月(「報告期」)的中期業績。 more info >> |
|
Friday, November 25, 2022 |
|
雅各臣公布二零二三财年中期业绩 |
从事基础药物、专科药物及品牌医疗保健品研发、生产、市场推广及销售的领先企业 ─ 雅各臣科研制药有限公司 (「 雅各臣 」 或 「 公司 」;股份代号 2633.HK ) 今天公布公司及其附属公司(统称「集团」)于截至二零二二年九月三十日止年度(「报告期」)的中期业绩。 more info >> |
|
雅各臣公佈二零二三財年中期業績 |
從事基礎藥物、專科藥物及品牌醫療保健品研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司 (「 雅各臣 」 或 「 公司 」;股份代號 2633.HK ) 今天公佈公司及其附屬公司(統稱「集團」)於截至二零二二年九月三十日止年度(「報告期」)的中期業績。 more info >> |
|
Jacobson Pharma Announces FY2023 Interim Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2022 (the "Reporting Period"). more info >> |
|
Wednesday, June 29, 2022 |
|
雅各臣公布二零二二财年全年业绩 |
从事基础药物、专科药物及品牌医疗保健品研发、生产、市场推广及销售的领先企业 ─ 雅各臣科研制药有限公司 (「 雅各臣 」或「 公司 」; 股份代号: 2633.HK )今天公布公司及其附属公司(统称「集团」)于截至二零二二年三月三十一日止年度(「二零二二财年」或「报告期」)的全年业绩。 more info >> |
|
雅各臣公佈二零二二財年全年業績 |
從事基礎藥物、專科藥物及品牌醫療保健品研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司 (「 雅各臣 」或「 公司 」; 股份代號: 2633.HK )今天公佈公司及其附屬公司(統稱「集團」)於截至二零二二年三月三十一日止年度(「二零二二財年」或「報告期」)的全年業績。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Theinvestmedia.com Offers Exclusive Brokerage Account Opening Offers and In-Depth Tutorials, Empowering Investors with Precise Decision-Making
Jul 26, 2025 08:00 HKT/SGT
|
|
|
Theinvestmedia.com 提供独家开户优惠与深度教学,赋能投资者精准决策
Jul 26, 2025 08:00 HKT/SGT
|
|
|
Theinvestmedia.com 提供獨家開戶優惠與深度教學,賦能投資者精準決策
Jul 26, 2025 08:00 HKT/SGT
|
|
|
maxWin Receives Honesty Award 2025, Setting New Standards for Integrity in Online Gaming
Jul 25, 2025 20:00: JST
|
|
|
維立志博於聯交所主板成功上市
Jul 25, 2025 19:36 HKT/SGT
|
|
|
maxWin Receives Honesty Award 2025, Setting New Standards for Integrity in Online Gaming
Jul 25, 2025 19:00 HKT/SGT
|
|
|
维立志博于联交所主板成功上市
Jul 25, 2025 18:00 HKT/SGT
|
|
|
OMS Energy Recorded Significant Profits Growth in 2025FY, Roth Capital Rating it "Buy" with a Potential 40% Upside TP
Jul 25, 2025 17:18 HKT/SGT
|
|
|
OMS能源2025財年業績增長強勁 Roth Capital評級買入潛在升幅40%
Jul 25, 2025 17:18 HKT/SGT
|
|
|
OMS能源2025财年业绩增长强劲 Roth Capital评级买入潜在升幅40%
Jul 25, 2025 17:18 HKT/SGT
|
|
|
百仕達(1168)擬更名「Z Fin Limited」控股股東換股以行動彰顯信心和支持 轉型戰略升級前景看俏
Jul 25, 2025 17:03 HKT/SGT
|
|
|
百仕达(1168)拟更名“Z Fin Limited” 控股股东换股以行动彰显信心和支持 转型战略升级前景看俏
Jul 25, 2025 17:03 HKT/SGT
|
|
|
CWE held 'Lancang Mekong Green Course' Open Day to celebrate the 10th anniversary of the Nam Ngiep 2 Hydropower Station
Jul 25, 2025 16:25 HKT/SGT
|
|
|
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics
Jul 25, 2025 16:00 JST
|
|
|
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
Jul 25, 2025 13:31 JST
|
|
|
|
More News >> |
|
|
|
|
|